Jirillo E, Maffione A B, Greco B, Cannuscio B, Calvello R, Covelli V
Policlinico, Bari, Italy.
Immunopharmacol Immunotoxicol. 1993 Mar-Jun;15(2-3):307-19. doi: 10.3109/08923979309026001.
Previous studies have demonstrated that benzodiazepines (BDZ) (e.g. diazepam) inhibit immune responsiveness. Since these drugs are largely used in psychiatric patients it is of great importance to verify the existence of different types of BDZ, which are not suppressive for the immune system. In this framework, our results indicate that alprazolam and triazolam, two triazolo-BDZ, do not modify in vitro phagocytosis and killing exerted by normal human polimorphonuclear cells and monocytes. On the contrary, they significantly enhance T lymphocyte-dependent antibacterial activity in normal donors. These data support the concept that triazolo-BDZ and, in particular, alprazolam may represent more appropriate drugs for the treatment of psychiatric patients (e.g. patients with phobic disorders and/or migraine) who display immunodeficits.
先前的研究表明，苯二氮䓬类药物（BDZ）（如地西泮）会抑制免疫反应。由于这些药物在精神病患者中广泛使用，因此验证是否存在对免疫系统无抑制作用的不同类型的BDZ非常重要。在此框架下，我们的结果表明，两种三唑并苯二氮䓬类药物阿普唑仑和三唑仑，不会改变正常人多形核细胞和单核细胞的体外吞噬作用和杀伤作用。相反，它们显著增强了正常供体中T淋巴细胞依赖性抗菌活性。这些数据支持了这样一种观点，即三唑并苯二氮䓬类药物，特别是阿普唑仑，可能是治疗存在免疫缺陷的精神病患者（如恐惧症和/或偏头痛患者）的更合适药物。
